HTLV-1 mosaic
Protein is >95% pure as determined by SDS-PAGE.
Description
The E.Coli derived recombinant mosiac protein contains the gp21 and gp46 immunodominant regions, 374-400 amino acids and 190-201 amino acids. The protein is fused with GST at N-terminus.
Product Specs
Immunoreactive with sera of HTLV-I infected individuals
Product Science Overview
Human T-cell leukemia virus type 1 (HTLV-1) is a deltaretrovirus that infects a wide range of cells, primarily CD4+ and CD8+ T-lymphocytes . HTLV-1 is associated with several serious medical conditions, including adult T-cell leukemia/lymphoma (ATLL), HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP), and various inflammatory processes . The virus is endemic in regions such as Japan, sub-Saharan Africa, South America, the Caribbean, Iran, Romania, and Melanesia .
The HTLV-1 mosaic recombinant protein is a specially designed protein that contains immunodominant fragments from the HTLV-1 envelope proteins gp21 and gp46 . Specifically, it includes amino acids 374-400 from gp21 and 190-207 from gp46 . This recombinant protein is produced using proprietary chromatographic techniques to ensure high purity and is used primarily as an antigen in ELISA and Western blot assays .
The HTLV-1 mosaic recombinant protein is highly valuable in research and diagnostic applications. It serves as an excellent antigen for the early detection of HTLV infections, with minimal specificity problems . This makes it a crucial tool in the development of diagnostic assays and in understanding the immune response to HTLV-1.
Numerous vaccination research experiments have been conducted to prevent or control HTLV-1 infection. Various approaches have been explored, including DNA-based, dendritic-cell-based, peptide/protein-based, and recombinant vaccinia virus approaches . The HTLV-1 mosaic recombinant protein plays a significant role in these studies, particularly in the development of peptide/protein-based vaccines .
